Entheogen Resurgence
SERPNTS
1 other identifier
observational
102
1 country
1
Brief Summary
For the purpose of this anonymous, observational pilot survey, the investigators will define "entheogens" as substances, generally derived from plants, that are ingested in order to impact one's consciousness for therapeutic, religious, or spiritual purposes. This survey will focus on the naturalistic use of entheogens and other substances including kambo, ayahuasca, hapé, bufo, and sananga typically used in specific cultural and spiritual contexts for healing. There are substantial limitations to what the healthcare community knows about the intentions, motivations, experiences, health behaviors, and demographics of people who decide to participate in entheogen therapy centers or retreats and their willingness to participate in future research studies. The primary goal of this observational pilot survey is to collect self-reported, anonymous data from people who have opted to participate in entheogen therapy centers and retreats during the last five (5) years on the topics of their initial intentions, motivations, experiences, demographics, and willingness to participate in future entheogen research. With the support of established therapy and retreat centers, the research team will aim to collect 100 survey responses from unique, unidentified individuals who have participated in some form of entheogen therapy or treatment during the last five (5) years. Those who choose to fill out the survey will be at least 18 years of age, fluent in English, and self-reporting participation in therapy or a retreat which utilized entheogens in a naturalistic setting in the past five (5) years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 30, 2021
CompletedFirst Posted
Study publicly available on registry
September 13, 2021
CompletedStudy Start
First participant enrolled
September 16, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 12, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 12, 2022
CompletedJanuary 27, 2022
January 1, 2022
4 months
August 30, 2021
January 26, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Entheogen Use in Naturalistic Retreat & Therapeutic Settings
The primary outcome will be self-reported experiences related to entheogen use in naturalistic retreat and therapeutic settings.
Entheogen use will have occured within the last 5 years
Interventions
self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
Eligibility Criteria
People over the age of 18 years old who are fluent in English and have self-reported participation in entheogen therapy centers or retreats in naturalistic settings during the past five (5) years.
You may qualify if:
- \>18 years old
- Fluent in English
- Self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
You may not qualify if:
- Inability to provide informed consent
- Inability to complete the online questionnaire
- No self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
- Self-reported participation in therapy or a retreat in naturalistic setting that incorporated the use of entheogens greater than five (5) years ago
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Vireo Healthlead
Study Sites (1)
Vireo Health of New York
Queens, New York, 11373, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Stephen Dahmer, ND
Resurgent Biosciences, Inc.
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 30, 2021
First Posted
September 13, 2021
Study Start
September 16, 2021
Primary Completion
January 12, 2022
Study Completion
January 12, 2022
Last Updated
January 27, 2022
Record last verified: 2022-01